Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase.
暂无分享，去创建一个
X. Bertagna | M. Fleseriu | R. Leelawattana | R. Auchus | J. Newell-Price | J. H. Kim | A. Shimatsu | Eun Jig Lee | A. Lacroix | B. Biller | J. Findling | R. Pivonello | L. Tauchmanovà | F. Gu | A. Pedroncelli | A. Laplanche | P. O'Connell